SG152269A1 - Treatment of fungal infections - Google Patents
Treatment of fungal infectionsInfo
- Publication number
- SG152269A1 SG152269A1 SG200902844-0A SG2009028440A SG152269A1 SG 152269 A1 SG152269 A1 SG 152269A1 SG 2009028440 A SG2009028440 A SG 2009028440A SG 152269 A1 SG152269 A1 SG 152269A1
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- fungal infections
- antibody
- composition
- posaconazole
- Prior art date
Links
- 206010017533 Fungal infection Diseases 0.000 title 1
- 208000031888 Mycoses Diseases 0.000 title 1
- 241000228212 Aspergillus Species 0.000 abstract 1
- 108010020326 Caspofungin Proteins 0.000 abstract 1
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 abstract 1
- 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 abstract 1
- 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 abstract 1
- 229940121375 antifungal agent Drugs 0.000 abstract 1
- 239000003429 antifungal agent Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 abstract 1
- 229960003034 caspofungin Drugs 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 abstract 1
- 229960001589 posaconazole Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0409077.5A GB0409077D0 (en) | 2004-04-23 | 2004-04-23 | Treatment of fungal infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG152269A1 true SG152269A1 (en) | 2009-05-29 |
Family
ID=32344282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200902844-0A SG152269A1 (en) | 2004-04-23 | 2005-04-18 | Treatment of fungal infections |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7785571B2 (ru) |
| EP (3) | EP2044954A1 (ru) |
| JP (1) | JP2007533716A (ru) |
| KR (1) | KR20080024944A (ru) |
| CN (1) | CN1946424A (ru) |
| AT (1) | ATE424846T1 (ru) |
| AU (1) | AU2005235339B2 (ru) |
| BR (1) | BRPI0510052A (ru) |
| CA (1) | CA2564137A1 (ru) |
| CY (1) | CY1109121T1 (ru) |
| DE (1) | DE602005013197D1 (ru) |
| DK (1) | DK1737488T3 (ru) |
| EC (1) | ECSP067022A (ru) |
| ES (1) | ES2322171T3 (ru) |
| GB (1) | GB0409077D0 (ru) |
| HK (1) | HK1100320A1 (ru) |
| HR (1) | HRP20090261T1 (ru) |
| IL (1) | IL178565A0 (ru) |
| MA (1) | MA28717B1 (ru) |
| MX (1) | MXPA06012256A (ru) |
| NO (1) | NO20065246L (ru) |
| NZ (1) | NZ550450A (ru) |
| PL (1) | PL1737488T3 (ru) |
| PT (1) | PT1737488E (ru) |
| RU (1) | RU2380116C2 (ru) |
| SG (1) | SG152269A1 (ru) |
| SI (1) | SI1737488T1 (ru) |
| TN (1) | TNSN06339A1 (ru) |
| WO (1) | WO2005102386A1 (ru) |
| ZA (1) | ZA200608767B (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100113355A1 (en) * | 2007-04-27 | 2010-05-06 | Naresh Chennamsetty | Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90 |
| US20140242085A1 (en) * | 2011-08-12 | 2014-08-28 | Medical & Biological Laboratories Co., Ltd. | Methods and composition for testing, preventing, and treating aspergillus fumigatus infection |
| CN111116743B (zh) * | 2018-10-30 | 2022-01-28 | 迈威(上海)生物科技股份有限公司 | Hsp90抗体及其在抗真菌感染中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8915019D0 (en) | 1989-06-30 | 1989-08-23 | Matthews Ruth C | Medicaments |
| US5952300A (en) * | 1996-04-19 | 1999-09-14 | Merck & Co., Inc. | Antifungal compositions |
| GB0008305D0 (en) * | 2000-04-06 | 2000-05-24 | Neutec Pharma Plc | Treatment of fungal infections |
| BR0314763A (pt) | 2002-09-23 | 2005-07-26 | Schering Corp | Tratamento de infecções fúngicas |
-
2004
- 2004-04-23 GB GBGB0409077.5A patent/GB0409077D0/en not_active Ceased
-
2005
- 2005-04-18 WO PCT/GB2005/001478 patent/WO2005102386A1/en active Application Filing
- 2005-04-18 CA CA002564137A patent/CA2564137A1/en not_active Abandoned
- 2005-04-18 AT AT05734312T patent/ATE424846T1/de active
- 2005-04-18 DE DE602005013197T patent/DE602005013197D1/de active Active
- 2005-04-18 PL PL05734312T patent/PL1737488T3/pl unknown
- 2005-04-18 MX MXPA06012256A patent/MXPA06012256A/es not_active Application Discontinuation
- 2005-04-18 EP EP09000071A patent/EP2044954A1/en not_active Withdrawn
- 2005-04-18 RU RU2006141354/13A patent/RU2380116C2/ru not_active IP Right Cessation
- 2005-04-18 KR KR1020067024467A patent/KR20080024944A/ko active IP Right Grant
- 2005-04-18 US US11/587,020 patent/US7785571B2/en not_active Expired - Fee Related
- 2005-04-18 BR BRPI0510052-6A patent/BRPI0510052A/pt not_active IP Right Cessation
- 2005-04-18 ZA ZA200608767A patent/ZA200608767B/en unknown
- 2005-04-18 JP JP2007508962A patent/JP2007533716A/ja active Pending
- 2005-04-18 PT PT05734312T patent/PT1737488E/pt unknown
- 2005-04-18 SI SI200530660T patent/SI1737488T1/sl unknown
- 2005-04-18 AU AU2005235339A patent/AU2005235339B2/en not_active Ceased
- 2005-04-18 NZ NZ550450A patent/NZ550450A/en unknown
- 2005-04-18 SG SG200902844-0A patent/SG152269A1/en unknown
- 2005-04-18 DK DK05734312T patent/DK1737488T3/da active
- 2005-04-18 EP EP05734312A patent/EP1737488B1/en active Active
- 2005-04-18 ES ES05734312T patent/ES2322171T3/es active Active
- 2005-04-18 EP EP09000072A patent/EP2039369A1/en not_active Withdrawn
- 2005-04-18 CN CNA2005800127088A patent/CN1946424A/zh active Pending
-
2006
- 2006-10-15 IL IL178565A patent/IL178565A0/en unknown
- 2006-10-20 TN TNP2006000339A patent/TNSN06339A1/en unknown
- 2006-11-13 MA MA29450A patent/MA28717B1/fr unknown
- 2006-11-15 NO NO20065246A patent/NO20065246L/no not_active Application Discontinuation
- 2006-11-23 EC EC2006007022A patent/ECSP067022A/es unknown
-
2007
- 2007-05-08 HK HK07104924.6A patent/HK1100320A1/xx not_active IP Right Cessation
-
2009
- 2009-05-11 HR HR20090261T patent/HRP20090261T1/xx unknown
- 2009-06-09 CY CY20091100606T patent/CY1109121T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL214325A (en) | Antibody against cmet, a drug that includes and uses it | |
| IL244803B (en) | Human anti-beta antibodies and their use | |
| WO2004016750A3 (en) | FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | |
| WO2005120557A3 (en) | Inhibition of macrophage-stimulating protein receptor (ron) | |
| UA90457C2 (ru) | Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms | |
| WO2005010048A3 (en) | Rg1 antibodies and uses thereof | |
| WO2006033700A3 (en) | Her2 antibody composition | |
| WO2007016285A3 (en) | M-csf specific monoclonal antibody and uses thereof | |
| WO2010002478A3 (en) | Glycopeptide and uses thereof | |
| WO2005067956A3 (en) | Use of interleukin-21 for the treatment of autoimune diseases and allograft rejection | |
| WO2003075855A3 (en) | Antibodies against cancer antigen tmeff2 and uses thereof | |
| WO2006076525A3 (en) | Combination cancer therapy with anti-psma antibodies | |
| WO2007019373A3 (en) | Novel formulations comprising fenofibrate and a statin, and related methods of treatment | |
| WO2002075274A3 (fr) | Methode et trousse pour le suivi des maladies neurodegeneratives | |
| WO2003099217A3 (en) | Methods of treating bacterial infections and diseases associated therewith | |
| WO2008049990A3 (fr) | Utilisation d'un anticorps anti-cd151 pour le traitement du cancer | |
| GB0008305D0 (en) | Treatment of fungal infections | |
| WO2006137938A3 (en) | Antibody fragments for protection from pathogen infection and methods of use thereof | |
| SI1750744T1 (sl) | Zdravilo za zdravljenje gliviäśnih infekcij, zlasti aspergiloze | |
| SG152269A1 (en) | Treatment of fungal infections | |
| WO2003072727A3 (en) | EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER | |
| WO2005084671A3 (en) | Combination of voriconazole and an antifungal cyp2c19 inhibitor | |
| WO2006131953A3 (en) | Antibodies directed against the myelin basic protein recognising an epitope of cd64 and their use as immunosuppressants | |
| WO2007007152A3 (en) | Anti-madcam antibodies to treat metastatic cancers and chloroma | |
| WO2005048822A3 (en) | Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof |